www.fdanews.com/articles/87939-sosei-and-vectura-announce-completion-of-nva237-trial
SOSEI AND VECTURA ANNOUNCE COMPLETION OF NVA237 TRIAL
June 28, 2006
Sosei and Vectura Group have announced that their collaborative product, NVA237, a novel inhaled once-daily treatment for chronic obstructive pulmonary disease (COPD), had successfully completed a Phase IIb multiple dose-ranging clinical trial.
NVA237 is being developed and commercialized by Novartis both as a monotherapy and in combination with their once daily bronchodilator indacaterol, under the terms of a global licence agreement signed in April 2005.
The outcome of the study supports the progression of NVA237 and Novartis are proceeding as planned with the development program.